Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 27, 2025 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.

The shareholders and all other persons with meeting rights are invited to attend the Annual General Meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting and regarding the e-voting system) is available on the argenx website www.argenx.com and on www.abnamro.com/evoting.

The company’s annual report for the financial year ended December 31, 2024 is now available on its website www.argenx.com/investors/financial-reports.

Agenda

In addition to recurrent items on the agenda, such as the discussion and adoption of the 2024 annual accounts, an advisory vote on the company’s 2024 remuneration report, the discharge of the directors for their duties performed in 2024 and the authorization of the Board of Directors to issue shares and to limit or exclude pre-emptive rights in relation thereto, it is proposed to re-appoint Anthony Rosenberg as a non-executive director to the Board of Directors and to adopt a new remuneration policy.

The full agenda for the meeting as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available for inspection at the argenx offices. A free copy thereof may also be obtained by e-mailing This email address is being protected from spambots. You need JavaScript enabled to view it.. argenx would like to encourage shareholders to use the voting by (electronic) proxy option as referred to in the convocation.

About argenx 

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.

For further information, please contact:  

Media:

Ben Petok
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investors:

Alexandra Roy (US) 
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Lynn Elton (EU) 
This email address is being protected from spambots. You need JavaScript enabled to view it.